DOCSLIB.ORG

Supplementary Figure S4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Figure S4 18DCIS 18IDC Supplementary FigureS4 22DCIS 22IDC C D B A E (0.77) (0.78) 16DCIS 14DCIS 28DCIS 16IDC 28IDC (0.43) (0.49) 0 ADAMTS12 (p.E1469K) 14IDC ERBB2, LASP1,CDK12( CCNE1 ( NUTM2B SDHC,FCGR2B,PBX1,TPR( CD1D, B4GALT3, BCL9, FLG,NUP21OL,TPM3,TDRD10,RIT1,LMNA,PRCC,NTRK1 0 ADAMTS16 (p.E67K) (0.67) (0.89) (0.54) 0 ARHGEF38 (p.P179Hfs*29) 0 ATG9B (p.P823S) (0.68) (1.0) ARID5B, CCDC6 CCNE1, TSHZ3,CEP89 CREB3L2,TRIM24 BRAF, EGFR (7p11); 0 ABRACL (p.R35H) 0 CATSPER1 (p.P152H) 0 ADAMTS18 (p.Y799C) 19q12 0 CCDC88C (p.X1371_splice) (0) 0 ADRA1A (p.P327L) (10q22.3) 0 CCNF (p.D637N) −4 −2 −4 −2 0 AKAP4 (p.G454A) 0 CDYL (p.Y353Lfs*5) −4 −2 Log2 Ratio Log2 Ratio −4 −2 Log2 Ratio Log2 Ratio 0 2 4 0 2 4 0 ARID2 (p.R1068H) 0 COL27A1 (p.G646E) 0 2 4 0 2 4 2 EDRF1 (p.E521K) 0 ARPP21 (p.P791L) ) 0 DDX11 (p.E78K) 2 GPR101, p.A174V 0 ARPP21 (p.P791T) 0 DMGDH (p.W606C) 5 ANP32B, p.G237S 16IDC (Ploidy:2.01) 16DCIS (Ploidy:2.02) 14IDC (Ploidy:2.01) 14DCIS (Ploidy:2.9) -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 Log Ratio Log Ratio Log Ratio Log Ratio 12DCIS 0 ASPM (p.S222T) Log Ratio Log Ratio 0 FMN2 (p.G941A) 20 1 2 3 2 0 1 2 3 2 ERBB3 (p.D297Y) 2 0 1 2 3 20 1 2 3 0 ATRX (p.L1276I) 20 1 2 3 2 0 1 2 3 0 GALNT18 (p.F92L) 2 MAPK4, p.H147Y 0 GALNTL6 (p.E236K) 5 C11orf1, p.Y53C (10q21.2); 0 ATRX (p.R1401W) PIK3CA, p.H1047R 28IDC (Ploidy:2.0) 28DCIS (Ploidy:2.0) 22IDC (Ploidy:3.7) 22DCIS (Ploidy:4.1) 18IDC (Ploidy:3.9) 18DCIS (Ploidy:2.3) 17q12 0 HCFC1 (p.S2025C) 2 LCMT1 (p.S34A) 0 ATXN7L2 (p.X453_splice) SPEN, p.P677Lfs*13 CBFB 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 17 19 21 X 0 IGFN1 (p.D1166N) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 17 19 21 X 2 PIK3CA, p.H1047R 0 CCDC60 (p.E209K) TP53, p.R273C 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 0 INO80E (p.K86Sfs*45) 5 CBFB, p.X55_splice MYCL1, MPL WGD 0 CLIP2 (p.R448H) 0 IRF4 (p.Q395H) 2 MYH1 (p.Y353C) (19q12-q13.11) 0 CRY2 (p.D381H) ) TBX3 TP53, p.R249T PIK3CA, p.H1047R (0.37) 0 DACT3 (p.R286H) 0 ITGA9 (p.E967K) 2 RREB1, p.P997Rfs*40 0 KCTD3 (p.H403Y) CDK4 5 COPG1, p.I92V SDHC, FCGR2B,PBX1,TPR SDHC, FCGR2B,PBX1,TPR LMNA, PRCC, NTRK1, CD1D, B4GALT3, LMNA, PRCC,NTRK1,CD1D,B4GALT3, LMNA, PRCC, NTRK1, CD1D, B4GALT3, LMNA, PRCC,NTRK1,CD1D,B4GALT3, BCL9, FLG,NUP21OL,TPM3,TDRD10,RIT1 2 PIK3CA (p.H1047R) 0 DPPA2 (p.C96R) BCL9, FLG,NUP21OL,TPM3,TDRD10,RIT1 0 FLNA (p.I1620F) +61 0 KDM5B (p.G576R) +12 2 SPINK5, p.A621T BRAF, CREB3L2,TRIM24,EGFR BRAF, 0 KIAA1462 (p.Q893R) BRAF, CREB3L2,TRIM24,EGFR BRAF, 0 FLNA (p.K1621E) 0 MAATS1 (p.R419T) 5 LDB3, p.R31Q 2 PTPRZ1 (p.M710I) +38 +27 0 FYCO1 (p.E734Q) (12q14.1) 0 NELL1 (p.P628S) ERBB2, CDK12 +18 0 GRK5 (p.R190Q) 0 NOC2L (p.R213K) 2 SRF, p.V454I 2 SACS (p.S3505*) 0 GUF1 (p.P457S) 0 NUP210L (p.G612R) 5 PPAP2B, p.S254N 0 HEG1 (p.S722Y) 0 OR10AG1 (p.V193L) (7q33-q34) 2 SSFA2, p.G324E 0 IGF1R (p.E1037K) +13 0 PCSK2 (p.E90K) +3 0 IL17RA (p.V127L) 1q21.2-q31.1 2 SLC17A8 (p.N435H) TERT 0 PLCH2 (p.F717L) 5 SPEN, p.P677Lfs*132 0 KHDRBS2 (p.P202S) 0 PRRC2A (p.G1682E) 2 ZNF79, p.V156I +5 +32 0 KIAA1524 (p.N67S) 0 PTPN20B (p.L193F) 2 TBX3 (p.F133V) 0 KIAA1731 (p.P1682Qfs*5) 0 SEC24B (p.Q496K) 5 WIZ, p.R100W 0 KLRB1 (p.L12V) 0 SLC4A3 (p.L747R) (17q12) 3 CCSAP, p.Q104K 2 TP53 (p.R249T) 0 KPNA7 (p.T51M) 0 SLC6A13 (p.Q341E) GATA3p.R366* 0 LUZP4 (p.R5W) 0 SLFN14 (p.S83C) 4 TCF7L2, p.G308Sfs*16 0 MAMLD1 (p.W303C) ) 0 SNX13 (p.E515K) 3 SCN4A, p.E452K 2 WASF3 (p.P324R) 0 SRCRB4D (p.E459Q) FLGN TP53, p.Q192* ARID2 ATRX 0 MED12L (p.A1237S) +2 RECQL4 EPPK1 0 MUC16 (p.V3336F) 0 TIAM2 (p.P579S) 5 CKAP5, p.R1453C 2 GLUD2, p.R76H 2 ZC3H12B (p.E316K) 0 NKAPL (p.R321K) 0 TNFRSF1A (p.A357V) 0 NR1H3 (p.V218I) 0 TP53 (p.R273C) TCF7L2 0 NUP188 (p.S1126Cfs*9) 0 TRIM13 (p.E387K) 1 BCL11B, p.T435I 3 ATR (p.T1798A) 0 TSTD2 (p.G364D) 5 FHAD1, p.E1034V +3 +4 +93 0 OPRM1 (p.A19V) 0 OR2A14 (p.R219H) Chromosome 0 TTN (p.I21107L) Chromosome Chromosome 1 FAM149A, p.L332I 0 ZFYVE27 (p.E148Q) Chromosome Chromosome 3 USP24 (p.S581N) 0 OR2B11 (p.A48T) +6 5 GATA3, p.E359Afs*44 RECQL4 EPPK1 TERT 0 ZNF407 (p.S586C) 0 OTUD3 (p.E172Vfs*19) 0 HSPA13 (p.S10L) +3 0 PARP14 (p.L223F) +4 +7 +9 1 FAM174A, p.A31V 1 CDC27 (p.N486H) 0 PCGF6 (p.Y340*) 5 PDCD7 (p.A2T) 5 S1PR5, p.S104F WGD 5 SPTBN4 (p.A2141V) GATA3, p.E359Afs*44 +5 (5p15.33) 0 PEX14 (p.G110S) 6 ERBB2 (p.D769H) ARID5B, CCDC6 ARID5B, CCDC6 +2 NUTM2B 1 KNOP1 (p.I218Sfs*41) 0 RAPGEF6 (p.F742Y) NUTM2B 6 ERBB2 (p.D904N) 5 SERPINI2, p.E341A 1 KLHL26, p.S179L 0 RRAGB (p.Q194*) 6 HYDIN (p.Q3905Rfs*5) +26 0 RSRC2 (p.R253Q) +0 22IDC 6 OR4K2 (p.D175G) 1 TBC1D16 (p.D210Y) 0 SETDB2 (p.K563*) 2 GPR119 (p.S6L) 16IDC 1 GATA3, p.R366* 1 MACF1, p.X4015_splice 18D 28IDC 0 SI (p.T279I) 2 SLITRK5 (p.R208W) MYC, p.V421I (8q24.3) 0 SIGLEC5 (p.A464P) 2 ADAMTS3 (p.Q430K) 16IDC 1 TBC1D16 (p.E214*) 14IDC NUTM2B 0 SLC46A2 (p.P273Lfs*31) 2 ADAMTS5 (p.R516C) 1 HOXD4, p.T162Ifs*7 1 PHF19, p.R217K 11 11 11 CDK4 CDK4 0 SLC7A5 (p.L349H) 2 BMP10 (p.W198R) 2 CDH26 (p.E267K) 0 GSTO1 (p.R147S) 0 SNCAIP (p.D257N) SPEN, p.L2247Cfs*106 0 SORCS3 (p.R794Q) 2 CDK5R1 (p.R153C) 4 AMPD1, p.R112W 1 SAG, p.R179C 12 13 14 16 18 21 X 12 13 14 16 18 21 X 0 SP8 (p.D237N) 12 13 14 16 18 21 X 2 CPXM2 (p.A118V) SMO 0 PIBF1 (p.T757N) CDK12 NUTM2B MYCL1, MPL 0 ST6GAL2 (p.D191N) ERBB2, LASP1 2 GTPBP4 (p.N5T) CDK12 ERBB2, LASP1 4 ARL14EP, p.D38N 0 SYNCRIP (p.N285Tfs*22) 2 HIC1 (p.P265S) 1 SERPINA3, p.M290L +25 +4 +4 0 TUBGCP3 (p.E884K) 0 TFAP2D (p.X179_splice) 2 HSPG2 (p.D3515N) +26 MTOR BRIP1 2 KCNH8 (p.V1034L) MACF1 BCL11B 22DCIS 0 THRAP3 (p.N110D) 4 CPA1, p.R234C +20 2 KIF13A (p.A211V) 1 SERPINA3, p.M290K 0 TP53 (p.Q192*) +14 +13 +34 +2 0 ABCA13 (p.S3457R) CEP89 CCNE1, TSHZ3 CEP89 CCNE1, TSHZ3 2 KRT15 (p.R202C) (10q22.3) 0 TRIM4 (p.G465R) 0 USP29 (p.N188K) 2 NR2F1 (p.P23T) 4 EDN3, p.V179I +3 2 OIT3 (p.G428S) 6 GK2, p.N92S 28DCIS 28IDC 0 UTP20 (p.X1014_splice) (1p34.2) 0 ALDH1L2 (p.A848E) 2 PARS2 (p.P444R) 0 VPS4B (p.S248Kfs*2) 2 PTGS1 (p.R60H) 4 IRS2, p.R871W +15 0 WDFY3 (p.E928*) 2 RREB1 (p.L163Q) 6 MAPK8IP2, p.G227S 0 BRINP1 (p.D701E) 0 WRN (p.F763Lfs*14) 2 SERPINA11 (p.A15D) 0 ZBTB33 (p.S297*) 2 SERPINB13 (p.F201L) 4 ITIH5, p.V402I ERBB2, CDK12 ERBB2, CDK12 0 BRIP1 (p.I504M) 0 ZIM3 (p.K389N) 2 SHH (p.A389S) 6 PCMTD1, p.P342S 0 ZNF107 (p.C249Wfs*5) 2 SLC22A23 (p.P156R) 18IDC +8 0 ZNF341 (p.Q105K) 2 TEX15 (p.P1963S) 4 L1CAM, p.R322Q 0 CCNL1 (p.P5T) 0 ZNF653 (p.P409L) 18IDC 6 PEF1, p.L179V CCNE1 CCNE1 2 TMPRSS11D (p.A114V) 0 ZNHIT6 (p.N333K) 18DCIS 2 ZNF445 (p.A307D) 4 MYC, p.V421I 0 FGFRL1 (p.H485Lfs*66) 4 DHX9 (p.N30Tfs*43) 16DCIS 0 COL9A3 (p.G35Afs*53) +8 6 SPEN, p.L2247Cfs*106 0 KIAA1462 (p.Q182R) 4 FREM2 (p.A202T) 14IDC +6 0 MAP3K10 (p.L881Rfs*123) 4 GAK (p.A341T) 16DCIS 4 NCKAP1, p.G442S 0 HMGCS2 (p.L402M) 0 MSH3 (p.P63A) 4 GPATCH8 (p.R1023Q) 14DCIS 4 HEXDC (p.R327C) 6 AKR1C4, p.G298V 22IDC 0 PLEKHG2 (p.E264K) 4 INTS9 (p.M519I) 14DCIS 22DCIS 3 AP5S1 (p.Q82*) 4 SSC5D, p.T1321M 0 KCNH2 (p.Y827H) 4 ITPR2 (p.A445V) 28DCIS 3 DUSP27 (p.G697E) 3 FLG (p.E990K) 4 KCTD14 (p.R157C) 6 ATP8A1, p.I306V 0 KIAA0754 (p.E623D) 3 WEE2 (p.R546P) 4 KIFC2 (p.P771L) 4 TNC, p.R1843C 3 SLC7A9 (p.E244K) 4 MPG (p.R201W) 3 SLC7A9 (p.P248H) 4 NPAT (p.S1200Y) 6 BTRC, p.L389Ffs*5 0 MTOR (p.L219F) 4 PRPF18 (p.E309K) 4 SMO (p.D786N) 4 SKI (p.R282W) 4 SYNE2 (p.M3705I) 4 UCP3 (p.A231S) 6 CLTB, 0 PLA2G4E (p.H392Q) 4 TACC2 (p.V2378I) 4 USP8 (p.A798P) 4 TEX10 (p.H728N) 4 XPC (p.X207_splice) 4 USP9X (p.A479T) 4 ZBTB18 (p.S145G) 6 ERVV−2, p.A464S 0 PVRL4 (p.Q336Rfs*10) 4 SYNGR3 (p.P137T) 4 ZNF561 (p.H415Qfs*22) 4 TMEM26 (p.D253N) 100% 100% 4 AGGF1 (p.V202L) 100% 100% 100% Cancer cell fraction (%) Cancer20% cell40% fraction60% 80% (%) 1 AGGF1 (p.V202L) Cancer20% cell40% fraction60% 80% (%) 4 OR5H15 (p.R143W) 20% 40% 60% 80% 0 RTTN (p.A546D) 20% 40% 60% 80% Cancer cell fraction (%) Cancer20% cell40% fraction60% 80% (%) 0% 1 KCTD7 (p.N334D) 0% 0% 0% 1 LRP1 (p.D4193Rfs*9) 0% 0 SPATA31E1 (p.P288T) 1 SCYL2 (p.L395I) 28DCIS 28IDC 22DCIS 22IDC 1 TFDP2 (p.Q261K) 14DCIS 16DCIS 16IDC 18DCIS 18IDC Cancer CellFraction(%) Cancer CellFraction(%) Cancer CellFraction(%) Cancer CellFraction(%) Cancer CellFraction(%) 80% <CCF≤100% 60% <CCF≤80% 40% <CCF≤60% 20% <CCF≤40% 10% <CCF≤20% 0% <CCF≤10% CCF =0% 80% <CCF≤100% 60% <CCF≤80% 40% <CCF≤60% 20% <CCF≤40% 10% <CCF≤20% 0% <CCF≤10% CCF =0% 80% <CCF≤100% 60% <CCF≤80% 40% <CCF≤60% 20% <CCF≤40% 10% <CCF≤20% 0% <CCF≤10% CCF =0% 80% <CCF≤100% 60% <CCF≤80% 40% <CCF≤60% 20% <CCF≤40% 10% <CCF≤20% 0% <CCF≤10% CCF =0% 80% <CCF≤100% 60% <CCF≤80% 40% <CCF≤60% 20% <CCF≤40% 10% <CCF≤20% 0% <CCF≤10% CCF =0% 14IDC Cluster Cluster Cluster Cluster Cluster 5 4 3 2 1 6 5 4 2 0 3 2 1 0 4 3 1 0 6 5 4 2 1 13IDC 8DCIS 4DCIS 13DCIS 8IDC 4IDC (0.69) G H (0.43) F (0.61) (0.56) J (0.61) I (0) 0 A2ML1, p.A593S 0 A2M, p.V868M 0 AGBL3, p.V400I 0 ADAMTSL4, p.R528C 0 DCAF8L2, p.V587M KMT2A PIK3CA, p.H1047R 0 ANKRD33B, p.A274S 0 APC, p.A1591V 10DCIS 12DCIS 0 DISP2, p.A45T 10IDC 0 C12orf10, p.R253* 0 COL6A2, p.V812L 0 ERRFI1, p.L118Qfs*2 0 CCAR1, p.L106* SS18L1, TSHZ2 HLF, MSI2,CLTC,PPM1D, CD79B,DDX5 0 FANCD2, p.H1320Q 12IDC 0 KIAA1377, p.A763T −4 −2 −4 −2 −4 −2 −4 −2 −4 −2 −4 −2 −4 −2 −4 −2 Log2 Ratio Log2 Ratio −4 −2 Log2 Ratio Log2 Ratio Log2 Ratio Log2 Ratio −4 −2 Log2 Ratio Log2 Ratio Log2 Ratio Log2 Ratio 0 CYP19A1, p.R457* 0 2 4 0 2 4 0 2 4 0 2 4 0 2 4 0 2 4 0 2 4 0 2 4 0 2 4 0 2 4 0 FLYWCH1, p.E19V (0.61) CCND1 CALR(19p13.2-13.11) LYL1, DDIT3,CDK4,MDM2,PTPRB NAB2, STAT6, ETV6, CDKN1B,KRAS,PPFIBP1,H3F3C( KDM5A, ERC1,CCND2,CHD4,ZNF384, (0.28) (0.37) 0 GABRA2, p.R94* +10 0 KMT2A, p.P3515Lfs*36 0 ECT2L, p.I31T MED23 PIK3CA, p.E545D PIK3CA, p.H1047L TP53, p.V73Wfs*50 10DCIS (Ploidy:1.92) 12IDC (Ploidy:2.21) 12DCIS (Ploidy:2.03) 10IDC
Load more

Recommended publications
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • Regulation of Cardiac Progenitors by Combination of Mesp1 and ETS
    REGULATION OF CARDIAC PROGENITORS BY COMBINATION OF MESP1 AND ETS TRANSCRIPTION FACTORS A Dissertation by KUO-CHAN WENG Submitted to the Office of Graduate and Professional Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Chair of Committee, Fen Wang Co-Chair of Committee, Robert J. Schwartz Committee Members, James F. Martin Jiang Chang Head of Department, Fen Wang May 2014 Major Subject: Medical Science Copyright 2014 Kuo-Chan Weng ABSTRACT Heart disease remains the leading cause of death worldwide. By understanding the regulating networks during cardiac development we can exploit those networks to manipulate adult cells into cardiac progenitors and provide an alternative for repairing diseased hearts. Mesp1 is considered to have critical roles during cardiac development but the molecular mechanisms need to be further studied. The roles of ETS transcription factors have been primarily limited to hematopoietic differentiation and cancer progression. The ETS transcription factors are known to have proliferating roles and were hypothesized to also be involved in cardiac differentiation and may potentially be used for cell reprogramming. The first part of this study characterizes the expression pattern of Mesp1 protein in early mouse embryo from E6.5 to E9.5 and provides a full expression profile in differentiating embryoid bodies in vitro from the undifferentiated stage to Day10. Our work showed Mesp1 expresses in the posterior region of E6.5 embryo then starts migrating through the primitive streak toward anterior mesoderm and endoderm in E7.5. A Mesp1 linage tracing ES cell line was established, and it allowed us to trace the Mesp1 derived cell population.
    [Show full text]
  • Detailed Review Paper on Retinoid Pathway Signalling
    1 1 Detailed Review Paper on Retinoid Pathway Signalling 2 December 2020 3 2 4 Foreword 5 1. Project 4.97 to develop a Detailed Review Paper (DRP) on the Retinoid System 6 was added to the Test Guidelines Programme work plan in 2015. The project was 7 originally proposed by Sweden and the European Commission later joined the project as 8 a co-lead. In 2019, the OECD Secretariat was added to coordinate input from expert 9 consultants. The initial objectives of the project were to: 10 draft a review of the biology of retinoid signalling pathway, 11 describe retinoid-mediated effects on various organ systems, 12 identify relevant retinoid in vitro and ex vivo assays that measure mechanistic 13 effects of chemicals for development, and 14 Identify in vivo endpoints that could be added to existing test guidelines to 15 identify chemical effects on retinoid pathway signalling. 16 2. This DRP is intended to expand the recommendations for the retinoid pathway 17 included in the OECD Detailed Review Paper on the State of the Science on Novel In 18 vitro and In vivo Screening and Testing Methods and Endpoints for Evaluating 19 Endocrine Disruptors (DRP No 178). The retinoid signalling pathway was one of seven 20 endocrine pathways considered to be susceptible to environmental endocrine disruption 21 and for which relevant endpoints could be measured in new or existing OECD Test 22 Guidelines for evaluating endocrine disruption. Due to the complexity of retinoid 23 signalling across multiple organ systems, this effort was foreseen as a multi-step process.
    [Show full text]
  • ONCOPANEL (Popv3)
    ONCOPANEL (POPv3) TEST INFORMATION BACKGROUND: Somatic genetic alterations in oncogenes and tumor-suppressor genes contribute to the pathogenesis and evolution of human cancers. These alterations can provide prognostic and predictive information and stratify cancers for targeted therapeutic information. We classify these alterations into five tiers using the following guidelines: Tier 1: The alteration has well-established published evidence confirming clinical utility in this tumor type, in at least one of the following contexts: predicting response to treatment with an FDA-approved therapy; assessing prognosis; establishing a definitive diagnosis; or conferring an inherited increased risk of cancer to this patient and family. Tier 2: The alteration may have clinical utility in at least one of the following contexts: selection of an investigational therapy in clinical trials for this cancer type; limited evidence of prognostic association; supportive of a specific diagnosis; proven association of response to treatment with an FDA-approved therapy in a different type of cancer; or similar to a different mutation with a proven association with response to treatment with an FDA-approved therapyin this type of cancer. Tier 3: The alteration is of uncertain clinical utility, but may have a role as suggested by at least one of the following: demonstration of association with response to treatment in this cancer type in preclinical studies (e.g., in vitro studies or animal models); alteration in a biochemical pathway that has other known, therapeutically-targetable alterations; alteration in a highly conserved region of the protein predicted, in silico, to alter protein function; or selection of an investigational therapy for a different cancer type.
    [Show full text]
  • Aquaporin Channels in the Heart—Physiology and Pathophysiology
    International Journal of Molecular Sciences Review Aquaporin Channels in the Heart—Physiology and Pathophysiology Arie O. Verkerk 1,2,* , Elisabeth M. Lodder 2 and Ronald Wilders 1 1 Department of Medical Biology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; [email protected] 2 Department of Experimental Cardiology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +31-20-5664670 Received: 29 March 2019; Accepted: 23 April 2019; Published: 25 April 2019 Abstract: Mammalian aquaporins (AQPs) are transmembrane channels expressed in a large variety of cells and tissues throughout the body. They are known as water channels, but they also facilitate the transport of small solutes, gasses, and monovalent cations. To date, 13 different AQPs, encoded by the genes AQP0–AQP12, have been identified in mammals, which regulate various important biological functions in kidney, brain, lung, digestive system, eye, and skin. Consequently, dysfunction of AQPs is involved in a wide variety of disorders. AQPs are also present in the heart, even with a specific distribution pattern in cardiomyocytes, but whether their presence is essential for proper (electro)physiological cardiac function has not intensively been studied. This review summarizes recent findings and highlights the involvement of AQPs in normal and pathological cardiac function. We conclude that AQPs are at least implicated in proper cardiac water homeostasis and energy balance as well as heart failure and arsenic cardiotoxicity. However, this review also demonstrates that many effects of cardiac AQPs, especially on excitation-contraction coupling processes, are virtually unexplored.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • SNP Genotypes of Olfactory Receptor Genes Associated with Olfactory Ability in German Shepherd Dogs
    SHORT COMMUNICATION doi: 10.1111/age.12389 SNP genotypes of olfactory receptor genes associated with olfactory ability in German Shepherd dogs † ‡ – M. Yang*, G.-J. Geng , W. Zhang , L. Cui§, H.-X. Zhang and J.-L. Zheng‡ † *Police-dog Technology Department, National Police University of China, Shenyang, Liaoning 110034, China. Technology Department, ‡ Shenyang Traffic Police Detachment, Shenyang, Liaoning 110001, China. Forensic Medicine Department, National Police University of China, Shenyang, Liaoning 110854, China. §Document Inspection Department, National Police University of China, Shenyang, Liaoning – 110854, China. Mark Inspection Department, National Police University of China, Shenyang, Liaoning 110854, China. Summary To find out the relationship between SNP genotypes of canine olfactory receptor genes and olfactory ability, 28 males and 20 females from German Shepherd dogs in police service were scored by odor detection tests and analyzed using the Beckman GenomeLab SNPstream. The representative 22 SNP loci from the exonic regions of 12 olfactory receptor genes were investigated, and three kinds of odor (human, ice drug and trinitrotoluene) were detected. The results showed that the SNP genotypes at the OR10H1-like:c.632C>T, OR10H1-like:c.770A>T, OR2K2-like:c.518G>A, OR4C11-like: c.511T>G and OR4C11-like:c.692G>A loci had a statistically significant effect on the scenting abilities (P < 0.001). The kind of odor influenced the performances of the dogs (P < 0.001). In addition, there were interactions between genotype and the kind of odor at the following loci: OR10H1-like:c.632C>T, OR10H1-like:c.770A>T, OR4C11-like:c.511T>G and OR4C11-like:c.692G>A(P< 0.001).
    [Show full text]
  • Dietary Chemoprevention Studies in Preclinical Models of Prostate Cancer: Bioactive Lipids and Vitamin D
    Dietary Chemoprevention Studies in Preclinical Models of Prostate Cancer: Bioactive Lipids and Vitamin D. Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Justin Bruce Smolinski, B.S. Ohio State University Nutrition (OSUN) Graduate Program The Ohio State University 2010 Dissertation Committee: Professor Steven K. Clinton, Advisor Professor Charles L. Brooks Professor Kichoon Lee Professor Mark L. Failla i Copyright by Justin Bruce Smolinski 2010 ii ABSTRACT Epidemiological evidence suggests that prostate cancer can be modulated by diet. Data exists that implicate both bioactive lipids and the vitamin D/ calcium axis in prostate cancer pathogenesis. These data suggest that bioactive lipids such as omega-3 fatty acids protect against prostate cancer, whereas omega-6 fatty acids promote prostate cancer. Population studies also indicate that a diet high in vitamin D decreases prostate cancer risk while calcium increases risk for prostate cancer, possibly by lowering circulating levels of protective vitamin D. In contrast, recent epidemiological studies indicate that vitamin D does not protect against prostate cancer, indicating that the role of vitamin D and calcium in this disease process is far from established. Importantly, crucial animal experiments are lacking that may serve to provide mechanistic data for the roles of these nutrients. The objective of the first study conducted in this dissertation was to evaluate and compare prostate carcinogenesis in murine models that utilize the SV40 Tag transformation system- TRAMP and Apt121/Rbf. These are commonly used models in prostate cancer chemoprevention studies. We characterized these models with respect to time to tumor development, tumor size and metastasis.
    [Show full text]
  • Topoisomerase Ii Inhibitors Induce an Illegitimate Genome Rearrangement Common in Infant Leukemia
    TOPOISOMERASE II INHIBITORS INDUCE AN ILLEGITIMATE GENOME REARRANGEMENT COMMON IN INFANT LEUKEMIA by Bhawana Bariar A dissertation submitted to the faculty of The University of North Carolina at Charlotte in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biology Charlotte 2013 Approved by: ______________________________ Dr. Christine Richardson ______________________________ Dr. Mark Clemens ______________________________ Dr. Laura Schrum ______________________________ Dr. Pinku Mukherjee ______________________________ Dr. Anthony Fodor ii ©2013 Bhawana Bariar ALL RIGHTS RESERVED iii ABSTRACT BHAWANA BARIAR. Topoisomerase II inhibitors induce an illegitimate genome rearrangement common in infant leukemia. (Under the direction of DR. CHRISTINE RICHARDSON) Infant acute leukemias account for ~30% of all malignancy seen in childhood across the Western world. They are aggressive and characterized by rapid onset shortly after birth. The majority of these have rearrangements involving the MLL (mixed lineage leukemia) gene. Although MLL fusion to more than 75 genes have been identified, AF9 is one of its most common translocation partners. Since MLL breakpoint sequences associated with infant acute leukemia are similar to those in secondary AML following exposure to the topoisomerase II (topo II) poison etoposide, it has been hypothesized that exposure during pregnancy to biochemically similar compounds may promote infant acute leukemia. Some studies have shown an epidemiological link between bioflavonoid intake
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Pdf Sub-Classification of Patients with a Molecular Alteration Provides Better Response [57]
    Theranostics 2021, Vol. 11, Issue 12 5759 Ivyspring International Publisher Theranostics 2021; 11(12): 5759-5777. doi: 10.7150/thno.57659 Research Paper Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation Qin He1, Wenjie Huang2, Danfei Liu1, Tongyue Zhang1, Yijun Wang1, Xiaoyu Ji1, Meng Xie1, Mengyu Sun1, Dean Tian1, Mei Liu1, Limin Xia1 1. Department of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China. 2. Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases; Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Clinical Medicine Research Center for Hepatic Surgery of Hubei Province; Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Public Health, Wuhan, Hubei, 430030, China. Corresponding author: Dr. Limin Xia, Department of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China; Phone: 86 27 6937 8507; Fax: 86 27 8366 2832; E-mail: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.12.29; Accepted: 2021.03.17; Published: 2021.03.31 Abstract Background: Since metastasis remains the main reason for HCC-associated death, a better understanding of molecular mechanism underlying HCC metastasis is urgently needed.
    [Show full text]